A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China Hai-Yan TuJifeng FengYi-Long Wu Original Research Article Open access 12 January 2022 Pages: 1 - 13
A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies Toshio ShimizuYasutoshi KubokiKyu-pyo Kim Original Research Article Open access 29 November 2021 Pages: 15 - 24
Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study David WaterhouseLaura IadelucaLauren Bartolome Original Research Article Open access 29 December 2021 Pages: 25 - 33
Prognostic Differences of RAS Mutations: Results from the South Australian Metastatic Colorectal Registry Anas AlawawdehCynthia PiantadosiTimothy Jay Price Original Research Article 25 November 2021 Pages: 35 - 41
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System Monia SisiMichele FusaroliFrancesco Gelsomino Original Research Article Open access 13 January 2022 Pages: 43 - 51
Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice Lishi LinEgbert F. SmitAlwin D. R. Huitema Original Research Article Open access 11 December 2021 Pages: 53 - 59
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma Veronica MollicaMatteo SantoniFrancesco Massari Original Research Article 11 December 2021 Pages: 61 - 68
Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features Matt Shirley Adis Disease Management Open access 14 December 2021 Pages: 69 - 84
MYL-1402O: A Bevacizumab Biosimilar Arnold Lee Adis Biosimilar Brief Open access 15 December 2021 Pages: 85 - 88
Correction to: Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer Arnold Lee Correction Open access 10 November 2021 Pages: 89 - 89
Correction to: Durvalumab: A Review in Extensive-Stage SCLC Zaina T. Al-Salama Correction Open access 06 December 2021 Pages: 91 - 91
Correction to: Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features Matt Shirley Correction Open access 24 December 2021 Pages: 93 - 93